Genzyme unveils $540m expansion plan for manufacturing, R&D

27/09/2005 - US biotechnology major Genzyme officially opened four European facilities last week as part of a investment package eventually expected to cost $540 million (€449m).

The series of openings, which will see Genzyme become one of the largest biotechnolgy operations in Europe, with over 2,000 staff, includes.

a site in Geel, Belgium, for the production of recombinant monoclonal antibodies.
an $8 million centre at its UK manufacturing site in Haverhill, to carry out process development and clinical trial support for renal disease products;
a $157 million fill-and-finish plant for biologic medicines in Waterford, Ireland; and
a drug discovery research facility in Cambridge, UK, that will employ 150 people within five years.
The moves comes in the wake of a number of other large-scale investments in biological drugs production capacity, from the likes of Genentech, GlaxoSmithKline and Bristol-Myers Squibb.


link to full article in in-pharmatech.com